INO as a pulmonary vascular
relaxing agent has been used to treat PPHN, a common
accompaniment of MAS. Studies suggest that though
mortality statistics did not alter significantly, sustained
improvement in oxygenation with nitric oxide and better
oxygenation at initiation with ECMO may have important
clinical benefits. It has been speculated that adopting
specific lung expansion strategies with nitric oxide may
lead to reduced use of the more invasive ECMO. Novel
pharmacologic interventions like pentoxiphylline by
antiinflamatory property of preventing meconium
induced polymorph degranulation, CC10 and tezosentan
are awaiting trials with sufficient power before they come
to be used regularly in this scenario